Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07623473 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

Study acronym: NIMBLE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Trial Details
NCT Number NCT07623473
Lead Sponsor Herlev and Gentofte Hospital
Collaborators: NEYE Foundation, Direktør Michael Hermann Nielsens mindelegat, afd B, Toyota Foundation Denmark, Grosserer L. F. Foghts Fond Denmark, Beckett Foundation, P. A. Messerschmidt & hustrus Fond
Conditions
(from sponsor)		 Lung Cancer (Diagnosis), Nodule, Solitary Pulmonary
Related terms Disease, Lung Neoplasms, Solitary Pulmonary Nodule
Enrollment 1,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov